|
시장보고서
상품코드
1964356
연조직 생물학적 제제 시장 규모, 점유율, 성장 분석 : 제품 유형별, 원료별, 용도별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Soft Tissue Biologics Market Size, Share, and Growth Analysis, By Product Type (Allografts, Synthetic Biologics), By Source (Human Donor Tissues, Animal-derived Tissues), By Application, By End-User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 연조직 생물학적 제제 시장 규모는 2024년에 74억 5,000만 달러로 평가되었으며, 2025년 78억 5,000만 달러에서 2033년까지 119억 6,000만 달러로 성장할 전망입니다. 예측 기간(2026-2033년) 동안 CAGR은 5.4%로 예측됩니다.
세계 연조직 생물학 시장은 인대, 힘줄, 근막 치유를 위한 혈소판풍부혈장(PRP), 성장인자 매트릭스, 세포외 매트릭스 스캐폴드 등의 제품에 초점을 맞추고 있습니다. 고령화와 신체활동량 증가에 따른 근골격계 손상 증가로 인해 최소침습적 재생의료에 대한 수요가 증가하고 있는 것이 주요 시장 촉진요인입니다. 이러한 바이오로직스 제품은 회복 기간을 단축하고 장기적인 의료 비용을 절감할 수 있어 합성 임플란트에서 치료 전략을 전환하는 역할을 하고 있습니다. 투자와 임상시험이 급증하는 한편, 규제 명확화와 유리한 상환 구조가 이러한 제품의 채택을 촉진하고 있습니다. 또한, 제조 기술의 발전으로 비용이 절감되고 신흥 시장 진입이 용이해졌으며, 임상 센터와의 제휴를 통해 실제 임상 데이터를 강화하여 환자 결과 개선을 통해 시장 침투를 촉진하고 있습니다.
세계 연조직 생물학적 제제 시장의 촉진요인
스포츠 손상, 직업적 스트레스, 노화에 따른 퇴행성 질환의 발생률 증가는 연조직 복구 및 재건에 대한 수요를 견인하고, 임상 현장에서 생물학적 제제 솔루션의 필요성을 높이고 있습니다. 의료 전문가들은 보다 빠르고 확실한 치유 과정을 촉진하는 재료를 적극적으로 찾고 있으며, 제조업체는 이러한 치료 요건에 부합하는 제품을 혁신하고 제공해야 합니다. 이러한 임상적 요구와 제품 효능의 시너지 효과는 다양한 수술 분야에서 폭넓은 수용을 촉진하고, 상업화의 길에 대한 투자를 장려하며, 연조직 생물학적 제제의 임상 적용 확대를 통해 성장을 촉진하고, 궁극적으로 환자와 의료 시스템 모두에 이익을 가져다 줄 수 있습니다.
세계 연조직 생물학적 제제 시장의 억제요인
세계 연조직 생물학적 제제 시장은 까다로운 R&D 프로세스, 엄격한 규제 기준, 전문적인 제조 능력의 필요성으로 인해 심각한 제약에 직면해 있습니다. 이러한 요인들은 신규 진입자의 장벽이 될 수 있는 막대한 초기 비용과 제품 개발 파이프라인의 진행 속도를 저해하는 결과를 초래합니다. 높은 자본 지출은 종종 소규모의 혁신적 기업을 멀리하게 하고, 기존 기업들은 리스크가 낮은 사업에 집중하도록 유도합니다. 그 결과, 임상에서 사용할 수 있는 제품의 폭이 좁아지고, 경쟁의 역학이 제한되며, 기업이 재정적, 규제적 문제를 해결하면서 결국 시장 성장을 저해하는 결과를 초래할 수 있습니다.
세계 연조직 생물학적 제제 시장 동향
세계 연조직 생물학적 제제 시장에서는 조직 특이적 제품 혁신을 향한 두드러진 추세를 볼 수 있습니다. 각 제조업체들은 다양한 연조직 수복 요건을 충족하는 바이오로직스에 집중하고 있습니다. 이러한 커스터마이징에 중점을 두어 재료 특성, 전달 메커니즘, 분해 특성을 개선하여 궁극적으로 임상 결과를 개선하고 외과 의사의 선호도에 부합하는 것을 목표로 하고 있습니다. 복잡한 생물학적 지식을 전문적인 제품 제공으로 전환하기 위해서는 생체재료 과학자, 임상의사, 규제 전문가 간의 협력 강화가 필수적입니다. 그 결과, 상업적 전략은 타겟팅된 증거 창출, 의료진을 위한 전문 교육 제공, 우수한 연구 기관과의 파트너십을 통한 채택 촉진 및 해부학적 적응증 검증에 점점 더 중점을 두고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 연조직 생물학적 제제 시장 규모 : 제품 유형별 & CAGR(2026-2033년)
세계의 연조직 생물학적 제제 시장 규모 : 소스별 & CAGR(2026-2033년)
세계의 연조직 생물학적 제제 시장 규모 : 용도별 & CAGR(2026-2033년)
세계의 연조직 생물학적 제제 시장 규모 : 최종사용자별 & CAGR(2026-2033년)
세계의 연조직 생물학적 제제 시장 규모 & CAGR(2026-2033년)
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.03.23Global Soft Tissue Biologics Market size was valued at USD 7.45 Billion in 2024 and is poised to grow from USD 7.85 Billion in 2025 to USD 11.96 Billion by 2033, growing at a CAGR of 5.4% during the forecast period (2026-2033).
The global soft tissue biologics market is focused on products such as platelet-rich plasma, growth factor matrices, and extracellular matrix scaffolds designed to heal ligaments, tendons, and fascia. The rising demand for minimally invasive regenerative therapies, spurred by an aging population and increased physical activity leading to musculoskeletal injuries, is a key market driver. These biologics can shorten recovery periods and reduce long-term healthcare costs, moving treatment strategies away from synthetic implants. Investment and clinical trials have surged, while regulatory clarity and favorable reimbursement structures encourage the adoption of these products. Additionally, advancements in manufacturing technology lower costs, facilitating entry into emerging markets, while partnerships with clinical centers enhance real-world evidence and stimulate further market penetration through improved patient outcomes.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Soft Tissue Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Soft Tissue Biologics Market Segments Analysis
Global soft tissue biologics market is segmented by product type, source, application, end-user and region. Based on product type, the market is segmented into Allografts, Synthetic Biologics, Cellular Products and Other Product Type. Based on source, the market is segmented into Human Donor Tissues, Animal-derived Tissues and Synthetic Materials. Based on application, the market is segmented into Orthopedic Surgery, Plastic & Reconstructive Surgery, Dental & Oral Surgery, Sports Medicine, Wound Care and Others. Based on end-user, the market is segmented into Hospitals, Ambulatory Surgical Centers, Research Institutions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Soft Tissue Biologics Market
The increasing incidence of sports injuries, occupational stress, and age-associated degenerative disorders is driving the demand for soft tissue repair and reconstruction, thereby amplifying the need for biologic solutions in clinical settings. Healthcare professionals are actively pursuing materials that facilitate quicker and more reliable healing processes, prompting manufacturers to innovate and deliver products that align with these therapeutic requirements. This synergy between clinical demands and product efficacy fosters wider acceptance across various surgical disciplines, encourages investment in commercialization avenues, and propels growth through enhanced clinical application of soft tissue biologics, ultimately benefiting patients and healthcare systems alike.
Restraints in the Global Soft Tissue Biologics Market
The Global Soft Tissue Biologics market faces significant restraints primarily due to the demanding research and development processes required, alongside strict regulatory standards and the necessity for specialized manufacturing capabilities. These factors result in considerable initial costs that may hinder the entry of new players and impede the speed at which products can progress through development pipelines. High capital expenditure often discourages smaller, innovative companies, prompting established businesses to focus on lower-risk endeavors. Consequently, this leads to a reduction in the range of products available in clinical practice, constrains competitive dynamics, and ultimately hampers market growth as firms navigate financial and regulatory challenges.
Market Trends of the Global Soft Tissue Biologics Market
The Global Soft Tissue Biologics market is witnessing a significant trend towards tissue-specific product innovation, where manufacturers are honing in on biologics that cater to the distinct repair requirements of various soft tissues. This focus on customization enhances material properties, delivery mechanisms, and degradation characteristics, ultimately aiming to boost clinical outcomes and align with surgeon preferences. Enhanced collaboration among biomaterials scientists, clinicians, and regulatory experts is vital in converting complex biological insights into specialized product offerings. Consequently, commercial strategies are increasingly aimed at generating targeted evidence, providing specialized training for healthcare teams, and fostering partnerships with centers of excellence to facilitate adoption and validate anatomical applications.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
- Technology Analysis
- Case studies
Global Soft Tissue Biologics Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- Allografts
- Bone Allografts
- Soft Tissue Allografts
- Synthetic Biologics
- Hydrogels
- Scaffolds
- Cellular Products
- Stem Cells
- Platelet Rich Plasma
- Other Product Type
Global Soft Tissue Biologics Market Size by Source & CAGR (2026-2033)
- Market Overview
- Human Donor Tissues
- Animal-derived Tissues
- Synthetic Materials
Global Soft Tissue Biologics Market Size by Application & CAGR (2026-2033)
- Market Overview
- Orthopedic Surgery
- Plastic & Reconstructive Surgery
- Dental & Oral Surgery
- Sports Medicine
- Wound Care
- Others
Global Soft Tissue Biologics Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Ambulatory Surgical Centers
- Research Institutions
- Others
Global Soft Tissue Biologics Market Size & CAGR (2026-2033)
- North America (Product Type, Source, Application, End-User)
- US
- Canada
- Europe (Product Type, Source, Application, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Type, Source, Application, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Type, Source, Application, End-User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Type, Source, Application, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Organogenesis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aplagene
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MiMedx
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AlloSource
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Integra LifeSciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ReGenicin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Tissuetech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SBiB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eucure
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Orthofix Medical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vericel Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Arthrex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kerecis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celltex Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Osiris Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medtronic
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- 3M
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Covalon Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Wright Medical Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
(주말 및 공휴일 제외)
